Protocol signature-page completeness as a document-control measure

A protocol signature-page review can answer whether an expected document is present and matches a defined version. It cannot answer whether a signature is legally valid or whether study activity was properly authorized.

Method and evidence scope

I reviewed ICH E6(R3), 21 CFR Part 11, and FDA guidance on electronic systems, records, and signatures in clinical investigations. I extracted principles concerning essential records, version control, attribution, and electronic evidence. I used them to design a documentary completeness measure for a defined peptide research file population.

This is a qualitative review of public primary sources. It did not inspect study files, interview research personnel, or estimate a benchmark. The workflow and metric are derived inferences. Sponsors and research organizations must evaluate them against their protocols, systems, agreements, jurisdictions, and written procedures.

Define what should be present

Select a fixed set of studies, sites, or protocol versions and a cutoff time. For each item, record the study identifier, protocol number, version, effective date, expected signer role, expected repository, and source that establishes the requirement.

Classify the record as present and version-matched, present with discrepancy, expected but absent, not applicable, or unable to verify. A page that cannot be opened is unable to verify, not confirmed absent. A signature-page image without its protocol context should not be assumed to match.

Review documentary attributes

Compare the visible study, version, signer role, and repository receipt. Do not assess handwriting, intent, authority, or legal validity unless a qualified owner has defined and authorized such a review. Preserve the source document and review timestamp.

Route discrepancies to the sponsor, study, quality, regulatory, or legal owner named in the procedure. Record accepted ownership, disposition, and closure evidence. Administrative staff can request missing documents and maintain the register, but they should not backdate, edit, or replace source records.

Calculate the measure

The documentary completeness proportion is the number of eligible records that are present and version-matched divided by the eligible population. Report absent, discrepant, excluded, and unable-to-verify counts separately. If required-document rules changed during the period, stratify the result or avoid a direct comparison.

The measure shows documentary status at a cutoff time. It does not prove that a person reviewed the protocol, understood it, held proper authority, or conducted work under the correct version. It also cannot determine whether an electronic signature system is validated or compliant.

Limitations

The sources do not prescribe this exact metric or a universal threshold. E6(R3) applies to clinical trials, while other research settings may follow different frameworks. Part 11 and the FDA guidance apply according to the records, systems, and regulatory context.

This method was not tested for reviewer agreement, altered documents, duplicate signatures, repository latency, or the relationship between completeness and research quality. A local pilot should include qualified review of ambiguous versions and a documented rule for replaced or superseded pages.

References

• ICH E6(R3): Guideline for Good Clinical Practice
• eCFR: 21 CFR Part 11, Electronic Records and Signatures
• FDA: Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations